| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Neoisoliquiritin targets multiple biological pathways as a bioactive flavonoid glycoside. As a component of licorice, it may contribute to the anti-inflammatory, antioxidant, and other pharmacological effects of licorice. The compound's mechanism involves modulation of signaling pathways through its flavonoid structure. Its specific molecular targets include various enzymes and receptors involved in inflammation and oxidative stress.
|
|---|---|
| ln Vitro |
In vitro, Neoisoliquiritin is a bioactive component from Glycyrrhiza uralensis with potential anti-inflammatory and antioxidant activities. It belongs to the flavonoid class and is a glycoside. The compound is a flavonoid O-glycoside. Its bioactivity has been characterized in various cell-based assays. Neoisoliquiritin is used in natural product research for studying licorice constituents.
|
| ln Vivo |
In vivo, Neoisoliquiritin has been studied for its bioactive properties as a licorice constituent. As a flavonoid glycoside, it may contribute to the pharmacological effects of licorice including anti-inflammatory and antioxidant activities. The compound is found in Glycyrrhiza uralensis and Spatholobus suberectus. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties. The compound is typically administered orally or via injection in preclinical studies.
|
| Enzyme Assay |
In vitro enzyme assays for Neoisoliquiritin involve measuring its antioxidant and anti-inflammatory activities. Antioxidant activity is assessed using DPPH, ABTS, or other free radical scavenging assays. Anti-inflammatory activity is measured by assessing inhibition of pro-inflammatory cytokine production or COX/LOX activity. Enzyme inhibition assays may be performed to identify specific molecular targets. Assays are performed in appropriate buffer systems with positive controls such as known flavonoids.
|
| Cell Assay |
In vitro cell-based assays for Neoisoliquiritin are conducted in immune cells, cancer cell lines, and other relevant cell types. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Cell viability is assessed by MTT or CCK-8 assays. Anti-inflammatory activity is assessed by measuring cytokine levels by ELISA. Antioxidant activity is assessed by measuring intracellular ROS levels. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Neoisoliquiritin in vivo studies are conducted in animal models of inflammation, oxidative stress, and other diseases. Animals are treated with Neoisoliquiritin via oral administration or injection. Disease progression is monitored by appropriate endpoints. For anti-inflammatory studies, animal models of inflammation are used. For antioxidant studies, models of oxidative stress are employed. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Neoisoliquiritin (MW 418.39 g/mol, C21H22O9) is a flavonoid glycoside. It is isolated from Glycyrrhiza uralensis (licorice). The compound is soluble in DMSO and other organic solvents. It should be stored at 4°C, protected from light; in solvent, it is stable at -80°C for 6 months and at -20°C for 1 month. Neoisoliquiritin is a bioactive component used in natural product research.
|
| Toxicity/Toxicokinetics |
Neoisoliquiritin is generally well-tolerated in preclinical studies. The compound is a natural flavonoid glycoside from licorice with established safety profiles. Its bioactivity has been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Neoisoliquiritin belongs to the flavonoid class and is a glycoside. It has been reported that Neoisoliquiritin has been found in Spatholobus suberectus, and relevant data are available. See also: Glycyrrhiza glabra (partial).
Neoisoliquiritin is a bioactive flavonoid glycoside isolated from Glycyrrhiza uralensis (licorice). It belongs to the flavonoid O-glycoside class with an O-glycosidically linked sugar to the flavonoid backbone. The compound is an active substance found in licorice and Spatholobus suberectus. Its molecular formula is C21H22O9 with a molecular weight of 418.39 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C21H22O9
|
|---|---|
| Molecular Weight |
418.3940
|
| Exact Mass |
418.126
|
| CAS # |
59122-93-9
|
| PubChem CID |
5320092
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
743.5±60.0 °C at 760 mmHg
|
| Melting Point |
187-189 °C
|
| Flash Point |
263.3±26.4 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.707
|
| LogP |
0.76
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
589
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC(=CC=C1/C=C/C(=O)C2=C(C=C(C=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O
|
| InChi Key |
XQWFHGOIUZFQPJ-LXGDFETPSA-N
|
| InChi Code |
InChI=1S/C21H22O9/c22-10-17-18(26)19(27)20(28)21(30-17)29-13-6-7-14(16(25)9-13)15(24)8-3-11-1-4-12(23)5-2-11/h1-9,17-23,25-28H,10H2/b8-3+/t17-,18-,19+,20-,21-/m1/s1
|
| Chemical Name |
(E)-3-(4-hydroxyphenyl)-1-[2-hydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~66.67 mg/mL (~159.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3901 mL | 11.9506 mL | 23.9011 mL | |
| 5 mM | 0.4780 mL | 2.3901 mL | 4.7802 mL | |
| 10 mM | 0.2390 mL | 1.1951 mL | 2.3901 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
